 This study examined the potential use of nanoparticles as a delivery system for the combination of dostaxyl, DTX, a microtubule targeting agent, and thymokinone, TQ, in the treatment of human ductal carcinoma cells T47D. The results showed that the optimal size of the nanoparticle was 117.3 nanometers, which was smaller than the other two sizes tested. The nanoparticle DTX plus TQ formulation significantly inhibited the proliferation of T47D cells, leading to increased apoptosis and autophagy. Additionally, it arrested the cells at the G2-M phase, reduced the breast cancer stem cell population, and decreased the expression of genes associated with EMT. Overall, these findings suggest that co-delivery of DTX plus TQ using nanoparticles could be a promising strategy for treating breast cancer. This article was authored by Raghda S. Baadad and Mason H. Alcatib. We are article.tv, links in the description below.